Table. Characteristics of Nannizziopsis sp. infection in humans*.

Year (reference)	Age, y/sex	Country	Underlying condition or context	Species	Localization	Positive samples	Treatment	Outcome
2017 (this study)	52/F	France	HIV, living in Mali	Nannizziopsis sp.	Brain abscess	Cerebral biopsy, CSF	AmpB for 1 mo, then VCZ	Recovery but neurologic sequela after 2 mo
2015 (this study)	63/F	France	Leukemia, recent travel to Senegal	N. obscura	Brain abscess	Blood culture, CSF, ascites fluid	Not treated (death before diagnosis)	Death before diagnosis
2005 (2)	38/M	Germany	HIV, travel to Nigeria	N. obscura	Brain abscess	Needle aspiration of brain lesion	VCZ	Recovery without sequelae after 4 mo
2005 (5)	40/M	United States	HIV	N. infrequens	Lung	Bronchial washing	Not treated, considered as a contaminant	Recovery after treatment of CMV infection
2000 (3,4)	32/M	United States	Travel to Nigeria	N. hominis	Lymph nodes, heart, lungs, spleen, kidneys	3 lymph nodes	ITRA for 2 y	NA
1994 (3)	NA/M	United States	HIV	N. hominis	Right thigh mass	Deep muscle mass on the right thigh, right groin, buttock, and lung	ITRA	Death after 8 mo
1982 (1)	24/M	United States	Travel to Africa	N. obscura	Abscess in right ankle, osteomyelitis	2 biopsies of abscess in tibia	AmpB for 4 mo	Recovery after 4 mo

*AmpB, amphotericin B; CMV, cytomegalovirus; CSF, cerebrospinal fluid; ITRA, itraconazole; NA, not available; VCZ, voriconazole.